Abbott Splurges on Therasense
TheraSense, based in Alameda, Calif., makes and sells the FreeStyle blood glucose self-monitoring kit, and specializes in diabetes test systems that use small blood samples to produce rapid test results.
The $27 buyout price -- which comes out to $1.12 billion -- is a big premium to Therasense's Monday close of $20.30 and its 52-week high of $21.48. It's also more than five times the company's trailing 12-month revenue of about $196 million, although that revenue is growing at a roughly 150% rate. Therasense isn't currently profitable, but analysts expect it to earn 26 cents a share next year.
Therasense was recently up $6.40, or 31.5%, to $26.70 in Instinet premarket trading."Together with TheraSense, Abbott can build on its success in the blood glucose monitoring business," Abbott said in a release. "We will continue to promote both the MediSense and TheraSense products and brands. This transaction will allow us to better serve the needs of people with diabetes through advanced technology, a promising pipeline, a broader product line, and critical mass in research, development, sales and marketing." Abbott expects the acquisition to dilute earnings by 1 cent a share in 2004 and turn accretive thereafter. It will also result in "one-time charges" in the second quarter, primarily for in-process research and development, and "throughout 2004 for integration expenses." The transaction is also subject to approval by holders of a majority of TheraSense common stock at a special meeting of stockholders; regulatory approvals; and other closing conditions. The deal is expected to close in the second quarter of 2004.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV